View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
Events
UPCOMING EVENTS
- Spatial Biology for Immuno-Oncology | January, San Diego, CA (Program Partner)
- American Association for Cancer Research | April, Chicago, IL (Exhibitor)
SITC 2021
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Webcast Recording: Tissue-Based CDx Development and Image Analysis in a Regulated Space
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...
AACR Virtual Meeting 2021 – April 9-14, 2021
Flagship presented three posters at the show, including: #AACR2021 poster no. 433: Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation, in partnership with Leap...
SITC 2020
SITC 2020 November 9-14, 2020As we prepare our poster presentation for the (virtual) Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, we encourage you to register now (members register for FREE!)
Webinar: Digital Pathology with Integrated PD-L1 AI, hosted by Flagship and Gestalt Diagnostics
Join Flagship Biosciences and our partners Gestalt Diagnostics for this informative webinar featuring an overview and discussion of the value of a truly integrated, digital pathology platform, using Artificial Intelligence (AI) to aid in diagnostic decisions! Flagship...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
Tissue Based Companion Diagnostics in a Regulated Space
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
Flagship Spotlight: Roberto Gianani, MD
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
PUBLICATIONS/POSTERS
Comprehensive Image Analysis Of Immunostained NSCLC Tissues Provides Necessary Context For Immune Oncology Biomarker Profiling
Key Takeaways Manual pathology assessment is challenging and variable, limiting the data interpretation required for meaningful spatial biology analysis Unlike manual assessment, artificial intelligence and machine learning technologies analyze the complex...
Artificial Intelligence Assisted Macrophage Identification in Tumor Biopsies
Key Takeaways Classifying macrophages is important in understanding response to immunotherapy, but it may be challenging to do by eye Using an immunofluorescence-guided machine learning algorithm provided accurate macrophage classification This algorithm is useful in...
Analysis of Companion Diagnostic Potentials For Multifaceted PD-L1 Assays
ABSTRACT In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor status including tumor immune landscape. PD-L1/PD-1 checkpoint therapies...